Mary Caffrey

The second day of Patient-Centered Oncology Care® 2021 featured a panel discussion, “Oncology Care Transitions: Bridging the Gaps Across the Patient Journey.”

On the opening day of Patient-Centered Oncology Care, Robert Groves, MD, of Banner | Aetna, discussed the use of psychographics to predict health behavior in local populations.

Sanofi and Regeneron had previously announced an overall survival advantage of 29% over chemotherapy alone; the combination also had a progression-free survival benefit of 46%.

The prespecified analysis of DESTINY-Breast03 opened a Presidential Symposium September 18, during the European Society of Medical Oncology (ESMO) 2021 Virtual Congress, with the study’s lead author predicting a new standard of care and a commentator calling the results “startling.”

In May, results showed that cemiplimab (Libtayo, Regeneron/Sanofi) produced significant benefits: a 31% reduction in the risk of death and a 25% reduction in the risk of disease progression.

Patients with EGFR Exon20 insertion+ non–small cell lung cancer (NSCLC) make up approximately 1% to 2% of patients with NSCLC and have lacked treatment options.

This is the third approval for zanubrutinib, which is sold as Brukinsa by BeiGene.

David J. Reeves, PharmD, BCOP, of Butler University discusses encouraging results from a recent trial, along with safety questions about the types of patients who weren't studied but are likely to have small cell lung cancer.

Study authors found that knowing a patient’s minimal residual disease status can help pinpoint the right multiple myeloma therapy to improve overall and progression-free survival.

The sodium glucose co-transporter 2 (SGLT2) inhibitor reduced cardiovascular death and hospitalization for heart failure by 21% in results presented August 27 during the recent European Society of Cardiology Congress.

The chief of medical oncology and hematology at Bryn Mawr Hospital and associate principal investigator for Main Line Health's NCI Community Oncology Research Program discusses therapeutic advances along with ongoing challenges in enrolling patients with small cell lung cancer (SCLC) in clinical trials.

Gaucher disease is a rare metabolic condition that causes a fatty substance to build up in the organs and bones. Patients can suffer liver enlargement, anemia, and reduced platelets; they experience fatigue, bone infarctions, and permanent disability or death.

A simple intervention to get people to use salt substitute and cut their stroke risk—along with other cardiovascular events—has implications for developing countries with diets high in salt that have high rates of chronic disease.

In a paper being presented during ESC Congress 2021, authors from the University of Copenhagen use a registry to mimic 2 well-known trials, finding explanations for some, but not all, of the gap in risk reduction between them.

A new study unveiled on day 2 of ESC Congress 2021 showed finerenone, a nonsteroidal mineralocorticoid receptor antagonist, offers benefits to patients with mild to moderate CKD and type 2 diabetes.

EMPEROR-Preserved represents the first trial to show unequivocal benefits of any drug on major heart failure outcomes in patients with heart failure and preserved ejection fraction, the lead investigator said.

The 5-year update could help solidify the role of sodium glucose co-transporter 2 (SGLT2) inhibitors in treating heart failure, years after the first evidence of their effectiveness emerged.

The lack of approved treatments for heart failure with preserved ejection fraction has represented a significant unmet need for a condition that affects 50% of patients with heart failure, including large subgroups, such as older women.

Apar Kishor Ganti, MD, chair of the National Comprehensive Cancer Network Guidelines panel in small cell lung cancer, explains the thinking behind several new recommendations.

Due to unprecedented disruption and missed screenings during the pandemic, efforts to implement a 5-year performance period under the Radiation Oncology Model were extended twice.